Publications, Posters and Presentations
ANNUAL
REPORT 2023
Publications, Posters and Presentations
ANNUAL
REPORT 2023
Publications, Posters and Presentations
ANNUAL
REPORT 2023
PUBLICATIONS
Wiley, 29 Aug 2022
Other
The impact of coronavirus disease 2019 on genitourinary and prostate cancer care and clinical trials: A qualitative exploration of the Australian and New Zealand experience
Natasha A. Roberts, Haryana M. Dhillon, Catherine Paterson, Kathryn Schubach, Margaret McJannett, Australian and New Zealand Urogenital and Prostate Cancer Trials Group
The Lancet, 16 Oct 2022
TheraP
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
James P Buteau, Andrew J Martin, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M Joshua, Roslyn J Francis, Alison Y Zhang, Andrew M Scott, Sze-Ting Lee, Arun A Azad, Margaret M McJannett, Martin R Stockler, Scott G Williams, Ian D Davis, Michael S Hofman, for the TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Wiley, 25 Oct 2022
Other
Centralization and prospective audit of cystectomy are necessary: a commentary on the case for centralization, supported by a contemporary series utilizing the ANZUP cystectomy database
Pravin Viswambaram, Steve P. McCombie, Cynthia Hawks, D. Michael A. Wallace, Shomik Sengupta, Dickon Hayne
American College of Sports Medicine, 24 Feb 2023
Other
Efficacy and Feasibility of Pre-surgical Exercise in Bladder Cancer Patients Scheduled for Open Radical Cystectomy
Dennis R. Taaffe, Steve P. McCombie, Daniel A. Galvão, Robert U. Newton, Shane La Bianca, Suzanne K. Chambers, Nigel Spry, Favil Singh, Pedro Lopez, Oliver Schumacher, Cynthia Hawks, and Dickon Hayne
POSTERS
ASCO 2022, 3 Jun 2022
DASL-HiCaP (ANZUP 1801) Abstract #TPS5103
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate –a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localized prostate cancer (ANZUP 1801)
First Author: T Niazi
ASCO 2022, 4 Jun 2022
UNISoN (ANZUP 1602) Abstract #4537
Ipilimumab + nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma
First Author: C Gedye
MOGA 2022, 19 Aug 2022
P3BEP (ANZUP 1302)
P3 BEP: Randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours (ANZUP protocol 1302)
First Author: D Zebic
ESMO, 13 Sep 2022
PCR MIB (ANZUP 1502) Abstract #1002
PEMBROLIZUMAB WITH CHEMORADIOTHERAPY IN MUSCLE INVASIVE BLADDER CANCER ANALYSIS OF SAFETY AND EFFICACY OF THE PCR-MIB PHASE II CLINICAL TRIAL (ANZUP 1502)
First Author: A. Weickhardt
22 Feb 2023
DASL-HiCaP (ANZUP 1801) Abstract #TPS396
DASL-HiCaP: Darolutamide Augments Standard therapy for Localized very High-risk Cancer of the Prostate – a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localized prostate cancer (ANZUP 1801)
First Author: T Niazi
22 Feb 2023
P3BEP (ANZUP 1302) Abstract #TPS431
An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours: P3BEP (ANZUP protocol 1302)
First Author: D Zebic
22 Feb 2023
Other Abstract #393644
Trial in Progress – Exploring the activity of pseudoephedrine in treating retrograde ejaculation following RPLND in survivors of testicular cancer (PREPARE)
First Author: Ciara Conduit
22 Feb 2023
Other Abstract #394646
Trial in Progress – Primary retroperitoneal lymph node dissection for clinical stage II testicular germ cell tumour and its impact on health-related quality of life compared to chemotherapy or radiotherapy (PRESTIGE)
First Author: Ciara Conduit
22 Feb 2023
Other Abstract #372
Societal benefits of surrogate outcomes to support reimbursement decisions: the case of prostate cancer
First Author: Rafael Emilio de Feria Cardet
22 Feb 2023
EVOLUTION (ANZUP 2001) Abstract #394738
EVOLUTION: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (ANZUP 2001)
First Author: Shahneen Sandhu
EAU 23, 10 Mar 2023
BCG+MM (ANZUP 1301)
Adding Mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial: The BCG+MM Trial (ANZUP 1301)
First Author: Hayne D.
PRESENTATIONS
ASCO 2022, 5 Jun 2022
ENZAMET (ANZUP 1304) Abstract #5070
Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormonesensitive prostate cancer (mHSPC)
First Author: Davis ID
ASCO 2022, 5 Jun 2022
TheraP (ANZUP 1603)
177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: overall survival after median follow-up of 3 years (TheraP ANZUP protocol 1603).
First Author: Michael Hofman
EANM’22 Annual Congress, 31 Oct 2022
TheraP (ANZUP 1603)
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP ANZUP 1603): a biomarker analysis from a randomised, open-label, phase 2 trial
First Author: James P Buteau